PMID: 15228092Jul 2, 2004Paper

AT1 receptor blockade limits myocardial injury and upregulates AT2 receptors during reperfused myocardial infarction

Molecular and Cellular Biochemistry
Bodh I Jugdutt, V Menon

Abstract

Persistent left ventricular (LV) dysfunction after reperfused myocardial infarction (RMI) is a significant problem and angiotensin II (AngII) type 1 receptor (AT1R) blockers (ARBs) may limit reperfusion injury involving upregulation of AngII type 2 receptors (AT2R). To determine whether ARBs valsartan and irbesartan limit reperfusion injury and upregulate AT2R protein during RMI, we randomized dogs with anterior RMI (90 min ischemia; 120 min reperfusion) to 4 groups [valsartan (n = 6); irbesartan (n = 9); vehicle controls (n = 8); and sham (n = 6)] and measured serial in vivo hemodynamics, LV systolic and diastolic function, and inhibition of AngII pressor responses to the ARBs, and ex vivo infarct size, and regional AT1R and AT2R protein expression at the end of the reperfusion. Compared to the control group, both ARBs significantly limited the increase in left atrial pressure, promptly limited the deterioration of LV dP/dtmax, dP/dtmin, ejection fraction and diastolic function, limited infarct expansion and thinning, and limited infarct size. Importantly, both ARBs increased AT2R protein in the postischemic reperfused zone, with no change in AT1R protein. There were no changes in the sham group. The results suggest that limit...Continue Reading

Citations

Oct 11, 2005·American Journal of Physiology. Heart and Circulatory Physiology·Szilard VorosChristopher M Kramer
Aug 26, 2020·Journal of Cardiovascular Pharmacology and Therapeutics·Andrey V KrylatovLeonid N Maslov
Feb 27, 2007·Vascular Health and Risk Management·Bodh I Jugdutt
May 6, 2014·Current Hypertension Reports·Elena KaschinaU Muscha Steckelings
Aug 24, 2011·Cardiovascular Drugs and Therapy·Xianwei WangJawahar L Mehta
Nov 22, 2018·American Journal of Physiology. Heart and Circulatory Physiology·Mikhail Y MaslovMark A Lovich
Apr 3, 2021·Molecular Pharmacology·Arina RanjitAli Aghazadeh-Habashi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Cardiac Remodeling

Cardiac remodeling in response to a myocardial infarction is characterized by progressive ventricular dilatation, cardiac hypertrophy, fibrosis, and deterioration of cardiac performance. Discover the latest research on Cardiac Remodeling here.